Friday, June 5, 2026

Boehringer Ingelheim halts planned investment in Germany

Boehringer Ingelheim is discontinuing planned investments in Germany for the 2027 to 2030 period. According to the company, the total volume amounts to €900 million.

Company cites policy and operating environment

The group points to challenging conditions in Germany and to cost-cutting measures in the healthcare system. From the company’s perspective, this also includes rules that would require drugmakers to grant higher rebates to statutory health insurers in the future.

Focus shifts to other markets

Boehringer Ingelheim also refers to stronger momentum in other regions and the current geopolitical situation. The company highlights increasing pressure from the United States. It said that, like other pharma companies, it has entered into an arrangement with the US government that includes investing in manufacturing and R&D in the US in order to be exempt from potential pharma tariffs.

What the German spending was intended for

The investments that are now being halted were primarily earmarked for expanding infrastructure at German sites, including new laboratory buildings.

Context: ongoing debate about Germany as a pharma hub

The decision comes as Germany’s attractiveness as a pharma and biotech location is under scrutiny. In this broader context, it is also being noted that Biontech plans to close its Marburg plant and its Idar-Oberstein site by the end of 2027.